服用培美替尼要注意什么？

Drug introduction

Pemigatinib, a small molecule inhibitor of fibroblast growth factor receptor (FGFR) 1, FGFR2 and FGFR3, received accelerated approval in the US in April 2020 for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or other rearrangements, as tested in a US FDA-approved trial. Developed by Incyte, it is the first targeted therapy for cholangiocarcinoma in the United States.

The recommended dose of pemigatinib is 13.5 mg orally administered once daily on days 1-14 of a 21-day cycle with or without food until disease progression or unacceptable toxicity.

Pemigatinib received orphan drug designation in the United States in August 2019 for the treatment of myeloid/lymphoid neoplasms associated with eosinophilia and PDGFRA, PDGFRB, or FGFR1 rearrangements or PCM1-JAK2. Pemigatinib is also in clinical development in multiple countries around the world for the treatment of several other FGFR-driven malignancies (such as solid tumors, urothelial cancer).

take medicine

1. Patients should note that the tablets should be swallowed whole and do not crush, chew, split or dissolve the tablets. If a patient misses a dose of pemetinib by 4 hours or more or experiences vomiting, resume the next scheduled dose.

2. Patients should pay attention to bed rest during medication, avoid fatigue, avoid staying up late, and maintain adequate sleep.

3. During the medication period, you should pay attention to your diet, avoid tobacco and alcohol, and avoid eating spicy and irritating foods such as chili, spicy hotpot, barbecue, spicy hot pot, as well as greasy, raw and cold foods such as fried dough sticks, fried skewers, ice cream, and ice cream. You can eat more fresh vegetables and fruits to help supplement the vitamins, proteins and other nutrients your body needs. However, you should avoid eating grapefruit to prevent the components from interacting with the medicine and affecting the absorption of the medicine.

4. Patients who are allergic to any component of pemetinib should avoid using this drug, otherwise the patient may have allergic reactions, causing urticaria, rash, dyspnea, skin itching and other uncomfortable symptoms, affecting their health.

5. If the patient needs to use other drugs during the medication, he should consult a doctor in advance and clarify whether and how to take it under the guidance of the doctor to avoid interactions between drugs and affect the efficacy of the drug.

6. Pregnant women should avoid using this drug, otherwise it may cause adverse events such as fetal malformation, fetal growth retardation, and embryo-fetal death. Women of childbearing age should use effective contraceptive measures during use.

Recommended related articles: